New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs
Open Access
- 16 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10), e47631
- https://doi.org/10.1371/journal.pone.0047631
Abstract
Respiratory distress syndrome in preterm babies is caused by a pulmonary surfactant deficiency, but also by its inactivation due to various conditions, including plasma protein leakage. Surfactant replacement therapy is well established, but clinical observations and in vitro experiments suggested that its efficacy may be impaired by inactivation. A new synthetic surfactant (CHF 5633), containing synthetic surfactant protein B and C analogs, has shown comparable effects on oxygenation in ventilated preterm rabbits versus Poractant alfa, but superior resistance against inactivation in vitro. We hypothesized that CHF 5633 is also resistant to inactivation by serum albumin in vivo. Nineteen preterm lambs of 127 days gestational age (term = 150 days) received CHF 5633 or Poractant alfa and were ventilated for 48 hours. Ninety minutes after birth, the animals received albumin with CHF 5633 or Poractant alfa. Animals received additional surfactant if PaO2 dropped below 100 mmHg. A pressure volume curve was done post mortem and markers of pulmonary inflammation, surfactant content and biophysiology, and lung histology were assessed. CHF 5633 treatment resulted in improved arterial pH, oxygenation and ventilation efficiency index. The survival rate was significantly higher after CHF 5633 treatment (5/7) than after Poractant alfa (1/8) after 48 hours of ventilation. Biophysical examination of the surfactant recovered from bronchoalveolar lavages revealed that films formed by CHF 5633-treated animals reached low surface tensions in a wider range of compression rates than films from Poractant alfa-treated animals. For the first time a synthetic surfactant containing both surfactant protein B and C analogs showed significant benefit over animal derived surfactant in an in vivo model of surfactant inactivation in premature lambs.Keywords
This publication has 37 references indexed in Scilit:
- Injury and Inflammation from Resuscitation of the Preterm InfantNeonatology, 2008
- Structure of pulmonary surfactant membranes and films: The role of proteins and lipid–protein interactionsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2008
- Antenatal inflammation and lung injury: prenatal origin of neonatal diseaseJournal of Perinatology, 2008
- Therapeutic effects of exogenous surfactant enriched with dextran in newborn rabbits with respiratory failure induced by airway instillation of albuminPulmonary Pharmacology & Therapeutics, 2008
- Surfactant proteins B and C are both necessary for alveolar stability at end expiration in premature rabbits with respiratory distress syndromeJournal of Applied Physiology, 2008
- What’s new in surfactant?European Journal of Pediatrics, 2007
- Positive End-Expiratory Pressure Modifies Response to Recombinant and Natural Exogenous Surfactant in Ventilated Immature Newborn RabbitsNeonatology, 2006
- Acute and Sustained Effects of Lucinactant Versus Poractant-α on Pulmonary Gas Exchange and Mechanics in Premature Lambs With Respiratory Distress SyndromePediatrics, 2006
- Lung Function in Premature Lambs and Rabbits Treated with a Recombinant SP-C SurfactantAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Increase of C-Reactive Protein and Decrease of Surfactant Protein A in Surfactant after Lung TransplantationAmerican Journal of Respiratory and Critical Care Medicine, 1998